Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.
about
Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infantsTacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children.Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate.Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis.Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.Treatment of atopic dermatitis with pimecrolimus - impact on quality of life.Skin absorption through atopic dermatitis skin: a systematic review.Diagnosis and management of common dermatoses in children: atopic, seborrheic, and contact dermatitis.Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*.Two therapeutic challenges: periocular and genital vitiligo in children successfully treated with pimecrolimus cream.
P2860
Q28086973-B2F10CEC-F052-48AF-AB99-19AC3C9F57C3Q36153370-51FEBE3B-B40E-4EA1-ABC5-8BF6906A1A3BQ36861654-629785D1-88A8-4275-8523-4DA7A922F0CBQ36892767-6333F9EA-8D75-403A-9CBA-A5144792E20AQ37049981-8EFA71AA-DC75-4C18-9342-D5BCEE994817Q37865056-22D0BA90-51AF-4752-B4C3-8BD313B17D9CQ38084638-4BDDDE20-9FF4-475C-8495-CCD58DDADF80Q38123240-9EC83094-D993-4B5D-BCE6-F0F20D9FB7C8Q38536150-588B37B2-094F-482B-BA78-B6E026562E5DQ38957449-CD2C4C24-6DE7-43C2-8B46-916E7EC3DCC6Q46868092-F835CA1B-A553-49BF-927F-82AB320645E0Q46909164-CEDCE945-5004-475C-BB1A-912145C17839Q50889145-E4833FAD-EAC4-4B90-91E6-0EED95A3255A
P2860
Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Low systemic absorption and go ...... ter, 3-week, open-label study.
@en
Low systemic absorption and go ...... ter, 3-week, open-label study.
@nl
type
label
Low systemic absorption and go ...... ter, 3-week, open-label study.
@en
Low systemic absorption and go ...... ter, 3-week, open-label study.
@nl
prefLabel
Low systemic absorption and go ...... ter, 3-week, open-label study.
@en
Low systemic absorption and go ...... ter, 3-week, open-label study.
@nl
P2093
P2860
P1476
Low systemic absorption and go ...... ter, 3-week, open-label study.
@en
P2093
Alice B Gottlieb
David Pariser
Denise Barilla
Doris Staab
Graham Scott
Heinz Schmidli
Laurence F Eichenfield
Marie-Eve Ebelin
Pascale Burtin
Richard G Langley
P2860
P304
P356
10.1111/J.1525-1470.2005.00128.X
P577
2005-09-01T00:00:00Z